Population pharmacokinetic analysis of a long-acting recombinant factor IX-FC fusion protein (RFIXFC) in patients with severe haemophilia B

被引：0
|
作者：
Diao, L. [1 ]
Li, S. [2 ]
Nestorov, I. [3 ]
Jiang, H. [2 ]
机构：
[1] Biogen Idec Hemophilia, Waltham, MA USA
[2] Biogen Idec Hemophilia, Preclin & Clin Res, Waltham, MA USA
[3] Biogen Idec Inc, Pharmacometr, Cambridge, MA USA
来源：
HAEMOPHILIA | 2013年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：33 / 33
页数：1
相关论文
共 50 条
  • [41] PERIOPERATIVE MANAGEMENT OF PATIENTS WITH SEVERE HAEMOPHILIA A WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC)
    Bocchinfuso, S.
    O'Donovan, M.
    Singleton, E.
    Benson, J.
    Byrne, M.
    Ryan, K.
    O'Donnell, J. S.
    O'Connell, N. M.
    HAEMOPHILIA, 2021, 27 : 105 - 106
  • [42] Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX FC Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies
    Windyga, J.
    Kulkarni, R.
    Shapiro, A. D.
    Ragni, M. V.
    Pasi, K. J.
    Ozelo, M. C.
    Tsao, E.
    Allen, G.
    Mei, B.
    HAEMOPHILIA, 2016, 22 : 19 - 20
  • [43] Long-term safety and efficacy of recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis in children with hemophilia B: Longitudinal analysis of kids B-LONG and B-YOND
    Bennett, Carolyn M.
    Nolan, Beatrice
    Kulkarni, Roshni
    Fischer, Kathelijn
    Perry, David J.
    Barnes, Christopher
    Feng, Jingyuan
    Ferrante, Francesca
    Ramirez-Santiago, Alejandra
    Mei, Baisong
    Barnowski, Chris
    Allen, Geoffrey
    HAEMOPHILIA, 2016, 22 : 47 - 47
  • [44] Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX-Fc fusion protein: A randomized trial
    Ettingshausen, Carmen Escuriola
    Hegemann, Inga
    Simpson, Mindy L.
    Cuker, Adam
    Kulkarni, Roshni
    Pruthi, Rajiv K.
    Garly, May-Lill
    Meldgaard, Rikke M.
    Persson, Paula
    Klamroth, Robert
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2019, 3 (02) : 268 - 276
  • [45] Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China
    Zhou, Ting
    Wang, Shuyue
    Zhang, Yao
    Wu, Runhui
    Li, Hongchao
    PEDIATRIC BLOOD & CANCER, 2023, 70 (06)
  • [46] B-LONG: results from a Phase 3 study of safety, efficacy, and pharmacokinetics of long-lasting recombinant factor IX Fc Fusion Protein (rFIXFc)
    Powell, J.
    Ozelo, M. C.
    Pasi, J.
    Ragni, M.
    Valentino, L. A.
    Mahlangu, J.
    Manco-Johnson, M.
    Josephson, N.
    Perry, D.
    Pierce, G. F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 240 - 240
  • [47] Long-lasting recombinant factor FIX Fc fusion (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study
    Powell, J.
    Apte, S.
    Chambost, H.
    Hermans, C.
    Jackson, S.
    Josephson, N.
    Mahlangu, J.
    Ozelo, C. M.
    Peerlinck, K.
    Allen, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 358 - 358
  • [48] Analysis of clinical target joint bleeding on prophylactic regimens with recombinant Factor IX Fc fusion protein in patients with severe hemophilia B
    Powell, Jerry S.
    Perry, David
    Baker, Ross I.
    Shapiro, Amy
    Manco-Johnson, Marilyn J.
    Potts, James
    Robinson, Brian
    Mei, Baisong
    Pierce, Glenn F.
    HAEMOPHILIA, 2014, 20 : 94 - 94
  • [49] Post hoc analysis to evaluate the effect of recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis in adults and adolescents with target joints and hemophilia B
    Kulkarni, Roshni
    Pasi, K. John
    Liesner, Raina
    Hanabusa, Hideji
    Feng, Jingyuan
    Ferrante, Francesca
    Mei, Baisong
    Jain, Nisha
    HAEMOPHILIA, 2016, 22 : 44 - 44
  • [50] Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B
    Aiello, Andrea
    Mancuso, Maria E.
    Colombo, Alessio
    Teruzzi, Cristina
    Berto, Patrizia
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2020, 7 (01) : 40 - 49
12345